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Abstract: Acute generalized exanthematous pustulosis (AGEP) is a severe, usually drug-related
reaction, characterized by an acute onset of mainly small non-follicular pustules on an erythematous
base and spontaneous resolution usually within two weeks. Systemic involvement occurs in about
20% of cases. The course is mostly benign, and only in rare cases complications lead to life-threatening
situations. Recent studies highlight the importance of genetic variations in interleukin-36 receptor
antagonist gene (IL-36RN) in the pathogenesis of this disease. The physiopathology of AGEP
remains unclear, but an involvement of innate and acquired immune cells together with resident cells
(keratinocytes), which recruit and activate neutrophils via production of cytokines/chemokines such
as IL-17, IL-36, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor
alpha (TNFα) and chemokine (C-X-C motif) ligand 8 (CXCL8)/IL-8, has been postulated. Treatment
is based on the removal of the causative drug, supportive care, infection prevention and use of potent
topical or systemic steroids.
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1. Introduction
Cutaneous adverse reactions to drugs are common and encompass a variety of mild to severe
and life-threatening reactions. Acute generalized exanthematous pustulosis (AGEP) represents a
severe, usually drug-related skin reaction characterized by acute formation of sterile pustules on an
erythematous background, fever and neutrophilia.
2. Background and Epidemiology
While the clinical picture of drug-induced pustular eruptions in patients without any history of
psoriasis had already been described in 1968 by Baker and Ryan, the term AGEP was introduced by
Beylot et al. in 1980 [1,2]. AGEP is a rare adverse drug reaction with an incidence of one to five cases
per million per year [3], but it might be underreported. It can occur at any age and seems to be more
frequent in women [4].
3. Aetiology
Although many causative factors leading to AGEP have been described, it is, in over 90% of
cases, associated with the ingestion of drugs [5,6]. Aminopenicillins, pristinamycin, sulphonamides,
quinolones, hydroxychloroquine, terbinafin and diltiazem are the most frequent causative drugs [7].
In particular cases, AGEP is induced by bacterial, viral or parasitic infections (e.g., parvovirus
B19 [8,9], mycoplasma [10,11], cytomegalovirus [12], coxsackie B4 [13], Chlamydia pneumoniae [14],
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Escherichia coli [15], and echinococcus [16]), spider bites [17], herbal medications [18], lacquer [18],
mercury [19] and even psoralen combined with ultraviolet A (PUVA) treatment [20]. Finally venoms,
foods and xenobiotics have also been suspected to induce the reaction [21].
4. Genetic Background
The genetic predisposition for the development of AGEP is not known. There seems to be a
correlation between mutations in the IL-36RN gene, encoding the interleukine-36 receptor antagonist
(IL-36Ra), and the development of generalized pustular eruptions after drug intake. IL-36Ra has
an anti-inflammatory function and blocks the proinflammatory cytokines IL-36α, IL-36β and IL-36γ.
Mutations in the IL-36RN gene can result in uncontrolled IL-36 signalling and increased downstream
production of further proinflammatory cytokines and chemokines [22]. However, it is still unclear if
mutations in IL-36RN lead to AGEP or, rather, to a drug-induced generalized pustular psoriasis (GPP),
as it is described in some cases [23,24].
5. Pathogenesis
AGEP has been classified as a T cell-related sterile neutrophilic inflammatory response (type IVd
reaction) [25–27]. The activation, proliferation and migration of drug-specific cluster of differentiation
(CD) 4 and CD8 T cells play an important role in the development of AGEP (Figure 1), as supported
by the use of patch tests [17–20] and in vitro tests [21,22]. It is supposed that drug-specific cytotoxic
T cells and cytotoxic proteins such as granzyme B and perforin induce the apoptosis of keratinocytes,
leading to subcorneal vesicles [27,28]. Recently, it has also been shown that, besides in toxic epidermal
necrolysis (TEN), granulysin is also expressed by CD4 and CD8 T cells and natural killer (NK) cells
in different drug reactions including AGEP, suggesting that granulysin may also play a role in the
pathogenesis of AGEP [28]. Furthermore, in vitro tests have shown that drug-specific T cells in
AGEP patients produced significantly more chemokine (C-X-C motif) ligand 8 (CXCL8)/IL-8, a potent
neutrophil chemotactic chemokine [26–29]. CXCL8/IL-8 is thought to play a central role in the
formation of pustules by recruitment of neutrophils. The increased levels of IL-17 and IL-22 as well as
granulocyte-macrophage colony-stimulating factor (GM-CSF) in AGEP patients may also participate
in the strong neutrophilic activity by the synergistic effect on the production of CXCL8/IL-8 and
the prevention of apoptosis of the neutrophils [28,29]. Recent studies also described a higher level
of IL-17 expression by neutrophils, mast cells (MC), and macrophages, and a lower level by T cells,
in AGEP patients, indicating that innate cells may also be involved in the pathogenesis of AGEP [29].
Furthermore, a deficiency in the IL36-Ra in some AGEP patients seems to play a role, leading to
the increased expression of various proinflammatory cytokines and chemokines such as IL-1, IL-6,
IL-12, IL-23, IL-17, tumor necrosis factor alpha (TNFα) and CXCL8/IL-8, which can further enhance
neutrophilic recruitment and activation [22,23,30].
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Figure 1. Putative pathogenic mechanisms in acute generalized exanthematous pustulosis (AGEP). 
(A) In cases with drug involvement, the initial phase involves stimulation of drug-specific T cells and 
(B) their migration to the skin; (C) These T cells, possibly together with natural killer T (NKT) 
cells/natural killer (NK) cells are activated in the skin, where they induce apoptosis of keratinocytes 
through cytotoxic proteins and Fas/Fas ligand (FasL) interactions  resulting in the formation of 
subcorneal vesicles; (D) Furthermore, these T cells together with subsequently activated bystander 
and inflammatory cells (keratinocytes, dendritic cells (DC), MC, neutrophils) release various 
cytokines and chemokines; (E) which predominately lead to neutrophilic inflammation and the 
formation of pustules.  
In some AGEP patients, IL-5 expressed by infiltrating T cells may lead to the eosinophilia 
presented in about 30% of AGEP patients [26]. An elevated expression of TNFα in AGEP patients has 
been reported [31]. 
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(A) In cases with t, the initial phase involves stimulation of drug-spe ifi T cells
and (B) their migration to the skin; (C) These T cells, po sibly together ith t r l ( )
cells/natural kil er (NK) cel s are activated in the skin, where they induce apoptosis of keratinocytes
through cytotoxic proteins and Fas/ li resulting in the formation of
subcorneal vesicles; (D) Furthermore, these T cells together with subsequently activ ted bystander and
inflammatory cells (keratinocytes, dendritic c lls (DC), MC, neutrophils) release various cytokines and
chemokines; (E) w ich predominately lead to neutrophilic inflammation and the formation f pustules.
In some AGEP patients, IL-5 expressed by infiltrating T cells may lead to the eosinophilia
presented in about 30% of AGEP patients [26]. An elevated expression of TNFα in AGEP patients has
been reported [31].
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6. Clinical Features and Variants
Characteristically, patients with AGEP develop an acute rash with pinhead-sized pustules on an
erythematous oedematous base, starting in the main folds (axillary, inguinal and submammary areas)
and spreading quickly (within a few hours) on the trunk and limbs (Figure 2). The time period from
drug ingestion to reaction onset is usually within 48 h, with antibiotics having a median of 24 h [7].
There is an itching or sometimes burning sensation [3,32]. Mucosal involvement, especially orally,
is reported in about 20%–25% of patients but mostly in a limited extension and only on one mucosal
region [5].
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Besides the normal presentation of AGEP, several atypical variants and overlap syndromes have 
been described. For example, an overlap of AGEP and drug reaction with eosinophilia and systemic 
symptoms (DRESS) [35,36], or TEN [36–44], as well as an AGEP case with targetoid lesions [45,46] 
have been reported. A dozen of localized reactions have been reported, and referred to as acute 
localized exanthematous pustulosis (ALEP) [47–50]. In about 50% of patients, additional skin 
symptoms such as erythematous oedema of the hand and face, purpura, vesicles and blisters have 
been reported.  
Differential diagnosis of other pustular eruptions (such as bacterial or fungal infections, 
neutrophilic dermatoses, etc.) can mostly be excluded easily by clinical picture, history and 
histopathological findings. Acute GPP can present with the same clinical picture and may be difficult 
to distinguish, as the histopathological findings can sometimes not clearly distinguish between these 
two diseases (Table 1). The most important factor for the diagnosis is the quicker resolution time seen 
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Figure 2. (A) Widespread rash with numerous pinhead-sized pustules on an erythematous oedematous
base; (B) Flexural accentuation with characteristic collarette-shaped desquamation is typically observed
in AGEP.
Systemic inflammation signs in the acute phase of the disease include fever (>38.0 ˝C), leucocytosis
(>10,000/mL), elevated levels of C-reactive protein (CRP) and mostly increased levels of neutrophils
(>7000/mL). As mentioned above, 30% of patients also present an eosinophilia and in 75% of cases a
hypocalcaemia, probably related to hypoalbuminemia, is found [5,33]. Multiorgan involvement has
been rep rted in 17% of cases [33]. Skin eruptions are sometimes accompanied by lymphadenopathy
and occasi nally by hepatocellular dysfunction and cholestasis as well as nephritis. Lung and bone
marrow might lso be involved, leading to respira ory failure nd neutropenia, respectively [33].
One case with phenytoin-induced AGEP and cerebellar symptoms has been reported, while it is
unknown whether cerebellar symptoms were related to t drug reaction or to phenytoin toxicity [34].
AGEP usually shows a mild course but high fever or cutaneous superinfection can complicate the
process and lead to severe illness and sometimes life-threatening situations, especially in patients
of poor general condition. The reported mortality is under 5% [3,4]. Usually there is a spontaneous
resolution of skin lesions within two weeks with a very typical collarette-shaped desquamation in the
region of previous pustulosis [3,4].
Besides the normal presentation of AGEP, several atypical variants and overlap syndromes have
been described. For example, an overlap of AGEP and drug reaction with eosinophilia and systemic
symptoms (DRESS) [35,36], or TEN [36–44], as well as an AGEP case with targetoid lesions [45,46] have
been reported. A dozen of localized reactions have been reported, and referred to as acute localized
exanthematous pustulosis (ALEP) [47–50]. In about 50% of patients, additional skin symptoms such as
erythematous oedema of the hand and face, purpura, vesicles and blisters have been reported.
Differential diagnosis of other pustular eruptions (such as bacterial or fungal infections,
neutrophilic dermatoses, etc.) can mostly be excluded easily by clinical picture, history and
histopathological findings. Acute GPP can present with the same clinical picture and may be difficult
to distinguish, as the histopathological findings can sometimes not clearly distinguish between these
two diseases (Table 1). The most important factor for the diagnosis is the quicker resolution time seen
in AGEP. Recent studies described similarities in the pathogenesis of AGEP and GPP, like mutations in
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the IL-36Ra and an elevated expression of IL-17 [51]. DRESS typically presents with a morbilliform
rash spreading from the face to the rest of the body, but might present with pustules as well. DRESS
develops with a longer latent period of two to six weeks and mucous membranes and systemic
involvement are more common [52]. Stevens-Johnson syndrome (SJS) and TEN are characterized
by epidermal detachment and histological full-thickness epidermal necrosis [53]. Severe cases of
AGEP, especially those with mucosal involvement, might be difficult to distinguish from these entities,
and overlap forms have been described.
Table 1. Factors favoring the diagnosis of AGEP over pustular psoriasis.
AGEP Generalized Pustular Psoriasis
History of psoriasis
(family/personal) usually lacking often present
Distribution pattern initially predominance in the folds more generalized
Onset of pustules fast (hours or few days after use of medication) slower
Duration of pustules Shorter (rapid resolution in a few days, max. 15 days,after drug suspension) longer
Size of pustules tiny (pinhead) larger
Duration of eruption/fever shorter (resolution in a few days after drug suspension) longer
History of drug reaction usual uncommon
Recent drug administration very frequent less frequent
Arthritis rare about 30%
Histology single-cell necrosis of keratinocytes, edema of papillarydermis, vasculitis, exocytosis of eosinophils
papillomatosis, acanthosis,
tortuous or dilated vessels
7. Histopathological Findings
A histopathological examination should be performed to distinguish AGEP from other pustular
eruptions. The skin biopsy should include a pustule. Typically, the biopsy shows spongiform
subcorneal and/or intraepithelial pustules, an oedematous papillary dermis and perivascular infiltrates
with neutrophils and some eosinophils (Figure 3). In some cases, necrotic keratinocytes and
leucocytoclastic vasculitis can also be found. Histopathologically, it can be difficult to differentiate
AGEP from GPP. The presence of eosinophils, necrotic keratinocytes, a mixed interstitial and
mid-dermal perivascular infiltrate and absence of tortuous or dilated blood vessels favors AGEP,
while the presence of psoriasiform acanthosis is characteristic of GPP [24,54].
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8. Diagnosis
Diagnosis of AGEP can be made clinically with the support of histopathological findings as
well as patch tests. The EuroSCAR study group presented a standardized scoring system in 2001,
the AGEP validation score, including the morphology of skin lesions, the presence of fever, the clinical
course, and the laboratory and histopathological findings [4]. To identify the responsible drug in case
of polymedication, a patch test can be performed after complete skin resolution. The sensibility of
the patch test in AGEP is higher than in other drug reactions such as SJS or TEN (58% positive in
AGEP vs. 24% positive in SJS/TEN). A positive result often shows small pustules at the location of
testing [55–57].
9. Therapy
Discontinuation of the causative agent is the main objective. Due to the mostly benign and
self-limiting course, a supportive treatment based on topical steroids and disinfectant solutions during
the pustular phase and rehydrating lotions during the desquamative phase, as well as antipyretics,
is usually sufficient. In very extensive rashes, the intake of systemic steroids for a short time can be
discussed [4], although there is no evidence that they reduce disease duration: their use is empirical
and not supported by any randomized study. In one report, there was no difference between different
treatment regimens regarding the course and duration of the disease or the length of fever [6,18,58].
Two cases of steroid-induced AGEP have been reported [58].
10. Conclusions
Recent research has improved our understanding of the pathophysiology of the disease but
so far no markers have been identified that can predict which patients will develop the disease.
The establishment of precise diagnostic criteria in AGEP is definitely a fundamental basis for clinical
trials of quality [4]. There are currently no published randomized trials for a topical or systemic
therapy for AGEP. Such trials are difficult to perform in a rare disease but necessary to provide a
definitive answer. It is important to sensitize dermatologists and internists to this diagnosis as we feel
that this disease is underreported. Indeed, the rash is usually not life-threatening and has a high rate
of spontaneous resolution, so patients are not always referred to a dermatologist.
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